Valeant, Turing Would Face Subpoena Vote Under Democrats' Plan
- House Oversight members want to investigate price changes
- Senators McCaskill, Collins seek details from drugmakers
Drugmakers in the Crosshairs: Congress Probes Pricing
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG are the focus of two probes in Congress seeking to examine why the companies raised the prices of medications sharply after acquiring them.
In the House, Democrats are pushing for a vote to subpoena the chief executive officers of both drugmakers to hand over documents on price increases. The U.S. Senate’s Special Committee on Aging, meanwhile, will investigate drug pricing practices by Valeant, Turing and two others.